替奈普酶后静脉替罗非班在急性缺血性卒中中的随机临床试验
INSTANT 试验在中国 37 家医院纳入 359 例无大中血管闭塞或心源性栓塞、静脉替奈普酶后临床反应不足的急性缺血性卒中患者,随机接受静脉替罗非班或安慰剂。替罗非班组 90 天极佳结局(mRS 0-1)比例高于安慰剂组(63.8% vs 52.2%;RR 1.22,95%CI 1.02-1.46;P=.03),症状性颅内出血与 90 天死亡率两组均较低。
要点
- 替奈普酶后反应不足且无大中血管闭塞或心源性栓塞者,加用替罗非班可提高 90 天极佳结局。
- 替罗非班组 90 天极佳结局 63.8%,安慰剂组 52.2%,RR 1.22(95%CI 1.02-1.46;P=.03)。
- 48 小时症状性颅内出血替罗非班组 1 例(0.9%),安慰剂组 0 例;90 天死亡率 0.6% vs 1.6%。
核心结论
- 在无大中血管闭塞或心源性栓塞且静脉替奈普酶后临床反应不足的急性缺血性卒中患者中,加用静脉替罗非班提高 90 天极佳结局的可能性。
研究设计与样本
- 研究者发起的随机、双盲、安慰剂对照试验,在中国 37 家医院开展,纳入 359 例急性缺血性卒中患者。
- 入组标准为无大中血管闭塞或心源性栓塞病因,且替奈普酶输注后 4-24 小时内 NIHSS 序列评估显示无显著变化、神经功能恶化或波动。
- 替罗非班组 177 例,安慰剂组 182 例;358 例(99.7%)完成试验。
主要发现
- 90 天极佳结局(mRS 0 或 1)替罗非班组 113 例(63.8%),安慰剂组 95 例(52.2%),RR 1.22(95%CI 1.02-1.46;P=.03)。
- 48 小时内症状性颅内出血替罗非班组 1 例(0.9%),安慰剂组 0 例。
- 90 天死亡率替罗非班组 0.6%,安慰剂组 1.6%。
- 患者平均年龄 66 岁,女性 141 例(39.3%)。
关键数值与推荐
- 替罗非班用法:0.3 μg/kg/min 负荷输注 30 分钟,随后 0.075 μg/kg/min 持续输注至多 47.5 小时,于替奈普酶后 4-24 小时内启动。
- 口服抗血小板治疗(阿司匹林和/或氯吡格雷)安慰剂组于溶栓后 24 小时开始,替罗非班组于溶栓后 44 小时开始,所有患者持续至 90 天随访。
- 主要结局为 90 天极佳结局,定义为改良 Rankin 量表评分 0 或 1(范围 0-6,评分越高残疾越重)。
临床怎么用
- 对于无大中血管闭塞或心源性栓塞、静脉替奈普酶后临床反应不足的急性缺血性卒中患者,可考虑加用静脉替罗非班以改善 90 天功能结局。
- 使用替罗非班时需注意口服抗血小板药物启动时间延迟至溶栓后 44 小时,并监测症状性颅内出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although recent trials have shown benefit with early tirofiban after thrombolysis, its efficacy remains uncertain in patients with acute ischemic stroke who do not have a large or medium vessel occlusion or a cardioembolic source and who show an inadequate clinical response to intravenous tenecteplase. OBJECTIVE: To assess the efficacy and safety of intravenous tirofiban administered after an inadequate response to intravenous tenecteplase in this specific patient population. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, randomized, double-blind, placebo-controlled trial conducted at 37 hospitals in China, enrolling 359 patients with acute ischemic stroke, without large or medium vessel occlusion or cardioembolic etiology, and with an insufficient clinical response to intravenous tenecteplase (defined as no significant change from baseline, neurological deterioration, or neurological fluctuation based on serial assessment of the National Institutes of Health Stroke Scale score within 4-24 hours after infusion). Recruitment took place between April 24, 2024, and July 16, 2025, with final follow-up on October 11, 2025. INTERVENTIONS: Intravenous tirofiban (n = 177), administered as a 0.3-μg/kg/min bolus over 30 minutes, followed by a continuous infusion of 0.075 μg/kg/min for up to 47.5 hours, or matching placebo (n = 182), initiated within 4 to 24 hours after intravenous tenecteplase. Oral antiplatelet therapy (aspirin and/or clopidogrel) was started 24 hours after thrombolysis in the placebo group and 44 hours after thrombolysis in the tirofiban group and continued in all patients through 90-day follow-up. MAIN OUTCOMES AND MEASURES: The primary outcome was an excellent outcome (defined as a score of 0 or 1 on the modified Rankin Scale; range, 0-6, with higher scores indicating more severe disability) at 90 days. Safety outcomes included incidence of symptomatic intracranial hemorrhage within 48 hours and 90-day mortality. RESULTS: Among 359 patients randomized (mean age, 66 years; 141 females [39.3%]), 358 (99.7%) completed the trial. An excellent outcome at 90 days was observed in 113 patients (63.8%) in the tirofiban group and in 95 patients (52.2%) in the placebo group (risk ratio, 1.22; 95% CI, 1.02-1.46; P = .03). Symptomatic intracranial hemorrhage within 48 hours occurred in 1 patient (0.9%) in the tirofiban group and no patients in the placebo group; 90-day mortality was 0.6% and 1.6%, respectively. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke without large or medium vessel occlusion or a cardioembolic source who had an inadequate clinical response to intravenous tenecteplase, adjunctive intravenous tirofiban increased the likelihood of an excellent outcome at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05604638.
引用
- Liu X, Zhang F, Zhang C, et al. Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial. JAMA. 2026. PMID: 42100960. doi:10.1001/jama.2026.5245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。